The possibilities and challenges of Advanced Therapy Medicinal Products
How measure value of ATMP's: Treatments at the forefront of scientific innovation need new payment models
When: Wednesday January 29, 08.30-09.30, breakfast from 08.00
Where: Gamal Gästmatsalen, Medicon Village, Byggnad 302
- Pfizer Sweden: Marketing, Manufacturing and Science/Collaboration, Christoph Varenhorst, Country Medical Director
- How measure value of ATMPs: Treatments at the forefront of scientific innovation need new payment models, Ann-Charlotte Dorange, Health and Value Lead
Country Medical Director of Pfizer Sweden and associated professor of medicine. In his role at Pfizer, he provides the leadership to all in-country medical functions and is the country senior medical voice internally and externally.
Ann-Charlotte Dorange has a vast knowledge of the health care sector with over 20 years of experience. Her early research focused on the conditions and incentives for innovation and growth in the health care sector. The last twelve years her focus have been on market access and health technology assessment of pharmaceuticals and medical technologies. Dr. Dorange has spent her time both at governmental agencies, private institutions and at the pharma industry which has given her both an industry perspective as well as a payer perspective. Dr. Dorange currently is the country Health and Value Lead for Pfizer Sweden where she focuses mostly on preventive care and vaccination as well as ATMPs.